Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUCYE Conditioning for PCNSL Auto-HSCT
NCT03733327Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of busulfan, cyclophosphamide and etoposide in primary central nervous system lymphoma (PCNSL), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
busulfancyclophosphamideetoposide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT03733327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733327.